美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

艾格里房產

76.75

+0.24000.31%

盤後：76.750.00000.00%17:38 EST

成交量：197.49萬

成交額：1.51億

市值：88.21億

市盈率：44.83

高：77.16

開：77.00

低：75.44

收：76.51

52周最高：79.65

52周最低：68.98

股本：1.15億

流通股本：1.08億

量比：1.59

換手率：1.82%

股息：3.05

股息率：3.98%

每股收益(TTM):1.71

每股收益(LYR):1.78

淨資產收益率：3.48%

總資產收益率：2.33%

市淨率：1.55

市盈率(LYR):43.12

資料載入中...

總覽公司新聞資訊公告

西南證券：驅動基因陰性NSCLC市場空間廣闊雙(多)抗、IO+ADC方案齊頭並進

中國生物製藥(01177)：TQB2102「HER2雙抗ADC」HER2低表達乳腺癌III期臨牀試驗完成受試者入組

港股異動 | 石藥集團(01093)升逾3% 機構看好公司未來在EGFR ADC及研發平台將有更多對外授權合作機會

中國生物製藥(01177)：維特柯妥拜單抗「CLDN18.2 ADC」III期臨牀試驗完成受試者入組

Macrogenics, Inc.盤中異動股價大跌5.43%報1.66美元

貝達藥業：公司自研尚未有ADC產品項目立項

Pyxis Oncology宣佈臨時CEO任命及領導層交接，聚焦戰略重點與項目延續性

財報前瞻｜艾格里房產本季度營收預計增18.63%，機構觀點偏積極

千億藥明系，連環資本局

東方證券：IO和ADC為腫瘤頭部MNC焦點聯用將迎突破

每周股票覆盤：百利天恒（688506）EGFR×HER3雙抗ADC上市申請獲受理

優赫得在華拓展第六個適應症，去年上半年銷售額突破22億美金

德曲妥珠單抗胃癌新適應證獲批，填補臨牀治療空白

優赫得®在華獲批治療既往接受過一種含曲妥珠單抗治療方案的局部晚期或轉移性HER2陽性成人胃或胃食管結合部腺癌患者

優赫得在華獲批新適應症

南方财经网

全球首創！百利天恒ADC新藥IZA-BREN食管鱗癌適應症獲CDE受理，中國患者有望領先海外三年獲益

華福證券：首次覆蓋維立志博(09887)給予「買入」評級下一代IO和ADC療法全佈局

智通财经网

繼鼻咽癌後瞄準食管鱗癌二線治療百利天恒雙抗ADC第二項上市申請獲受理

每日经济新闻

雙抗ADC又一歷史性突破！百利天恒(688506.SH)iza-bren食管鱗癌上市申請獲受理

港股異動 | 映恩生物-B(09606)早盤升逾4% ADAM9靶向ADC癌症新藥在中國獲批臨牀

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ADC/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房產","latestPrice":76.75,"timestamp":1770843600000,"preClose":76.51,"halted":0,"volume":1974926,"hourTrading":{"tag":"盘后","latestPrice":76.75,"preClose":76.75,"latestTime":"17:38 EST","volume":174407,"amount":13385742.48221,"timestamp":1770849496640,"change":0,"changeRate":0,"amplitude":0.003257},"delay":0,"changeRate":0.0031368448568813863,"floatShares":108366822,"shares":114934390,"eps":1.712089,"marketStatus":"盤後交易","change":0.24,"latestTime":"02-11 17:50:15 EST","open":77,"high":77.16,"low":75.44,"amount":151027291.54388002,"amplitude":0.022481,"askPrice":77.89,"askSize":3,"bidPrice":75.27,"bidSize":26,"shortable":3,"etf":0,"ttmEps":1.712089,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1770858000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":76.51,"dividendRate":0.039792,"preHourTrading":{"tag":"盘前","latestPrice":76.6683,"preClose":76.51,"latestTime":"08:56 EST","volume":27,"amount":2067.5749499999997,"timestamp":1770818187096,"change":0.1583,"changeRate":0.002069,"amplitude":0.002069},"postHourTrading":{"tag":"盘后","latestPrice":76.75,"preClose":76.75,"latestTime":"17:38 EST","volume":174407,"amount":13385742.48221,"timestamp":1770849496640,"change":0,"changeRate":0,"amplitude":0.003257},"volumeRatio":1.585792,"impliedVol":0.0754,"impliedVolPercentile":0.0199},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","floatShares":108366822,"roa":"2.33%","roe":"3.48%","lyrEps":1.779999,"volumeRatio":1.585792,"shares":114934390,"dividePrice":3.054,"high":77.16,"amplitude":0.022481,"preClose":76.51,"low":75.44,"week52Low":68.98,"pbRate":"1.55","psRate":"12.81","week52High":79.65,"institutionHeld":0.9801,"latestPrice":76.75,"committee":0.793103,"eps":1.712089,"divideRate":0.039792,"volume":1974926,"delay":0,"ttmEps":1.712089,"open":77,"prevYearClose":72.03,"prevWeekClose":74.74,"prevMonthClose":72.23,"prevQuarterClose":72.03,"fiveDayClose":73.89,"twentyDayClose":71.41,"sixtyDayClose":73.7,"dividendPayoutRate":1.673137059483926,"dividendFrequency":"M","dividendGrowthYears":9,"dividendGrowthRate":0.027749229188078095,"fiveYearAvgDividendRate":0.040404410811749565},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC\",params:#limit:5,,,undefined,":[{"date":"2026-02-27","symbol":"ADC","amount":0.262,"announcedDate":"2026-02-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-27","defaultRemindTime":1772202600000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-13","payableDate":"2026-02-27","currency":"USD","dateTimestamp":1772168400000,"payDate":"2026-03-13"},{"date":"2026-02-10","symbol":"ADC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":1.07,"defaultRemindTime":1770757200000,"name":null,"time":"盤後","dateTimestamp":1770699600000,"actualEps":null},{"date":"2026-01-30","symbol":"ADC","amount":0.262,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-30","defaultRemindTime":1769783400000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-13","payableDate":"2026-01-30","currency":"USD","dateTimestamp":1769749200000,"payDate":"2026-02-13"},{"date":"2025-12-31","symbol":"ADC","amount":0.262,"announcedDate":"2025-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-31","defaultRemindTime":1767191400000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-15","payableDate":"2025-12-31","currency":"USD","dateTimestamp":1767157200000,"payDate":"2026-01-15"},{"date":"2025-11-28","symbol":"ADC","amount":0.262,"announcedDate":"2025-11-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-28","defaultRemindTime":1764340200000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-12","payableDate":"2025-11-28","currency":"USD","dateTimestamp":1764306000000,"payDate":"2025-12-12"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-29","recordDate":"2016-03-31","paymentDate":"2016-04-15","value":0.465,"currency":"USD"},{"executeDate":"2016-06-28","recordDate":"2016-06-30","paymentDate":"2016-07-15","value":0.48,"currency":"USD"},{"executeDate":"2016-09-28","recordDate":"2016-09-30","paymentDate":"2016-10-14","value":0.48,"currency":"USD"},{"executeDate":"2016-12-21","recordDate":"2016-12-23","paymentDate":"2017-01-03","value":0.495,"currency":"USD"},{"executeDate":"2017-03-29","recordDate":"2017-03-31","paymentDate":"2017-04-14","value":0.495,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.381,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.381,"analysts":21,"updateTime":1752123600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ADC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ADC","date":"2026-02-10","current":44.828277,"percent":0.811889,"low":31.539495,"twenty":37.639342,"median":41.778924,"eighty":44.506847,"high":53.261716,"avg":41.365532,"sd":4.459499,"marketCap":8639951367},"quantilePoints":[{"date":"2021-02-12","current":45.520618,"twenty":31.975443,"median":39.41667,"eighty":43.618647,"marketCap":4111649797},{"date":"2021-02-19","current":43.859591,"twenty":31.975443,"median":39.41667,"eighty":43.642628,"marketCap":4007933303},{"date":"2021-02-26","current":44.718497,"twenty":31.977009,"median":39.430911,"eighty":43.756513,"marketCap":4086420942},{"date":"2021-03-05","current":44.656157,"twenty":31.975443,"median":39.41667,"eighty":43.796506,"marketCap":4080724259},{"date":"2021-03-12","current":46.594043,"twenty":31.975443,"median":39.41667,"eighty":43.856021,"marketCap":4257810284},{"date":"2021-03-19","current":46.240217,"twenty":31.975443,"median":39.41667,"eighty":43.889974,"marketCap":4225477299},{"date":"2021-03-26","current":46.69811,"twenty":31.977009,"median":39.430911,"eighty":43.995818,"marketCap":4267319985},{"date":"2021-04-01","current":47.239256,"twenty":31.977009,"median":39.430911,"eighty":44.083322,"marketCap":4316770432},{"date":"2021-04-09","current":47.1005,"twenty":31.975443,"median":39.41667,"eighty":44.146464,"marketCap":4304090831},{"date":"2021-04-16","current":47.627771,"twenty":31.975443,"median":39.41667,"eighty":44.201737,"marketCap":4352273317},{"date":"2021-04-23","current":49.334461,"twenty":31.975443,"median":39.41667,"eighty":44.216631,"marketCap":4508232419},{"date":"2021-04-30","current":48.814129,"twenty":31.975443,"median":39.41667,"eighty":44.274005,"marketCap":4460683913},{"date":"2021-05-07","current":44.881383,"twenty":31.975443,"median":39.41667,"eighty":44.314742,"marketCap":4499986938},{"date":"2021-05-14","current":44.377456,"twenty":31.975443,"median":39.41667,"eighty":44.249425,"marketCap":4449461218},{"date":"2021-05-21","current":44.026621,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4414285084},{"date":"2021-05-28","current":44.830352,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4494870410},{"date":"2021-06-04","current":45.665977,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4578653566},{"date":"2021-06-11","current":45.646841,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4576734868},{"date":"2021-06-18","current":47.246871,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4737160278},{"date":"2021-06-25","current":48.748389,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4887708512},{"date":"2021-07-02","current":48.211648,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4833892628},{"date":"2021-07-09","current":49.210395,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4934031046},{"date":"2021-07-16","current":49.93058,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5006239701},{"date":"2021-07-23","current":50.956505,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5109102975},{"date":"2021-07-30","current":53.056971,"twenty":31.977009,"median":39.430911,"eighty":44.230599,"marketCap":5165308396},{"date":"2021-08-06","current":52.598062,"twenty":31.977009,"median":39.430911,"eighty":44.296692,"marketCap":5120631744},{"date":"2021-08-13","current":52.520401,"twenty":31.977009,"median":39.430911,"eighty":44.412506,"marketCap":5113071079},{"date":"2021-08-20","current":52.718085,"twenty":31.977009,"median":39.430911,"eighty":44.625208,"marketCap":5132316407},{"date":"2021-08-27","current":52.209754,"twenty":31.977009,"median":39.430911,"eighty":44.658936,"marketCap":5082828422},{"date":"2021-09-03","current":52.675724,"twenty":31.977009,"median":39.430911,"eighty":44.712504,"marketCap":5128192408},{"date":"2021-09-10","current":49.555141,"twenty":31.977009,"median":39.430911,"eighty":44.74795,"marketCap":4824391169},{"date":"2021-09-17","current":50.119952,"twenty":31.977009,"median":39.430911,"eighty":44.835833,"marketCap":4879377818},{"date":"2021-09-24","current":47.775985,"twenty":31.977009,"median":39.430911,"eighty":44.888065,"marketCap":4651183223},{"date":"2021-10-01","current":47.352376,"twenty":31.977009,"median":39.430911,"eighty":44.941549,"marketCap":4609943235},{"date":"2021-10-08","current":47.670083,"twenty":31.977009,"median":39.430911,"eighty":44.9864,"marketCap":4640873226},{"date":"2021-10-15","current":49.02563,"twenty":31.977009,"median":39.430911,"eighty":45.094688,"marketCap":4772841185},{"date":"2021-10-22","current":49.5269,"twenty":31.977009,"median":39.430911,"eighty":45.190701,"marketCap":4821641836},{"date":"2021-10-29","current":50.169373,"twenty":32.013133,"median":39.571166,"eighty":45.28245,"marketCap":4884189150},{"date":"2021-11-05","current":43.773853,"twenty":32.013133,"median":39.651928,"eighty":45.28245,"marketCap":4934976633},{"date":"2021-11-12","current":43.137928,"twenty":32.029424,"median":39.72736,"eighty":45.28245,"marketCap":4863283742},{"date":"2021-11-19","current":43.008274,"twenty":32.198132,"median":39.802558,"eighty":45.28245,"marketCap":4848666745},{"date":"2021-11-26","current":42.662528,"twenty":32.27459,"median":39.842867,"eighty":45.28245,"marketCap":4809688086},{"date":"2021-12-03","current":42.508177,"twenty":32.348817,"median":39.911012,"eighty":45.28245,"marketCap":4792286899},{"date":"2021-12-10","current":42.891493,"twenty":32.447032,"median":39.953188,"eighty":45.28245,"marketCap":4835501148},{"date":"2021-12-17","current":45.380751,"twenty":32.521786,"median":39.996581,"eighty":45.380751,"marketCap":5116135105},{"date":"2021-12-23","current":46.352906,"twenty":32.588031,"median":40.079057,"eighty":45.406143,"marketCap":5225733953},{"date":"2021-12-31","current":48.175698,"twenty":32.64443,"median":40.10618,"eighty":45.47788,"marketCap":5431231792},{"date":"2022-01-07","current":46.703962,"twenty":32.651599,"median":40.164071,"eighty":45.565296,"marketCap":5265311314},{"date":"2022-01-14","current":46.015352,"twenty":32.70478,"median":40.208708,"eighty":45.667046,"marketCap":5187678797},{"date":"2022-01-21","current":43.267663,"twenty":32.731462,"median":40.224323,"eighty":45.667046,"marketCap":4877909831},{"date":"2022-01-28","current":43.821252,"twenty":32.743358,"median":40.249944,"eighty":45.667046,"marketCap":4940320287},{"date":"2022-02-04","current":42.666817,"twenty":32.769192,"median":40.314701,"eighty":45.667046,"marketCap":4810171655},{"date":"2022-02-11","current":42.565551,"twenty":32.769192,"median":40.347561,"eighty":45.667046,"marketCap":4798755108},{"date":"2022-02-18","current":42.943612,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4841376882},{"date":"2022-02-25","current":37.784604,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4620036905},{"date":"2022-03-04","current":38.267307,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4679058463},{"date":"2022-03-11","current":37.29027,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4559593141},{"date":"2022-03-18","current":37.24956,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4554615419},{"date":"2022-03-25","current":38.110019,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4659826391},{"date":"2022-04-01","current":39.298046,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4805089927},{"date":"2022-04-08","current":39.763938,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4862056020},{"date":"2022-04-14","current":40.742313,"twenty":32.769192,"median":40.404479,"eighty":45.667046,"marketCap":4981684815},{"date":"2022-04-22","current":42.01187,"twenty":32.769192,"median":40.455317,"eighty":45.667046,"marketCap":5136917418},{"date":"2022-04-29","current":39.554287,"twenty":32.79826,"median":40.479695,"eighty":45.667046,"marketCap":4836421278},{"date":"2022-05-06","current":39.499614,"twenty":32.904642,"median":40.479695,"eighty":45.667046,"marketCap":5066773466},{"date":"2022-05-13","current":39.967203,"twenty":32.996397,"median":40.479695,"eighty":45.667046,"marketCap":5126753027},{"date":"2022-05-20","current":39.90291,"twenty":33.05702,"median":40.479695,"eighty":45.667046,"marketCap":5118505838},{"date":"2022-05-27","current":40.353768,"twenty":33.088236,"median":40.495181,"eighty":45.667046,"marketCap":5176339242},{"date":"2022-06-03","current":40.599257,"twenty":33.156377,"median":40.53176,"eighty":45.667046,"marketCap":5207829139},{"date":"2022-06-10","current":41.119461,"twenty":33.227354,"median":40.613635,"eighty":45.667046,"marketCap":5274557730},{"date":"2022-06-17","current":40.213488,"twenty":33.270165,"median":40.613635,"eighty":45.667046,"marketCap":5158345016},{"date":"2022-06-24","current":43.32302,"twenty":33.260026,"median":40.659236,"eighty":45.668114,"marketCap":5557217043},{"date":"2022-07-01","current":42.978166,"twenty":33.330747,"median":40.684242,"eighty":45.668114,"marketCap":5512981235},{"date":"2022-07-08","current":42.872956,"twenty":33.466784,"median":40.715658,"eighty":45.668114,"marketCap":5499485565},{"date":"2022-07-15","current":43.708789,"twenty":33.59929,"median":40.742313,"eighty":45.668114,"marketCap":5606701167},{"date":"2022-07-22","current":44.556311,"twenty":33.59929,"median":40.778643,"eighty":45.668114,"marketCap":5715416287},{"date":"2022-07-29","current":46.520226,"twenty":33.675236,"median":40.820493,"eighty":45.678143,"marketCap":5967335462},{"date":"2022-08-05","current":43.100932,"twenty":33.675236,"median":40.862996,"eighty":45.68777,"marketCap":6116022220},{"date":"2022-08-12","current":44.318758,"twenty":33.675236,"median":40.912721,"eighty":45.68777,"marketCap":6288831702},{"date":"2022-08-19","current":44.509569,"twenty":33.675236,"median":40.969109,"eighty":45.68777,"marketCap":6315907842},{"date":"2022-08-26","current":43.241234,"twenty":33.675236,"median":41.010201,"eighty":45.68777,"marketCap":6135931147},{"date":"2022-09-02","current":41.585665,"twenty":33.675236,"median":41.060268,"eighty":45.68777,"marketCap":5901005814},{"date":"2022-09-09","current":41.956063,"twenty":33.675236,"median":41.092655,"eighty":45.68777,"marketCap":5953565380},{"date":"2022-09-16","current":40.805583,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5790312183},{"date":"2022-09-23","current":39.935707,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5666876838},{"date":"2022-09-30","current":37.927001,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5381841428},{"date":"2022-10-07","current":36.428553,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5169211706},{"date":"2022-10-14","current":35.631626,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5056127734},{"date":"2022-10-21","current":36.636203,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5198677248},{"date":"2022-10-28","current":38.359137,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5443161610},{"date":"2022-11-04","current":41.724424,"twenty":33.675236,"median":41.119461,"eighty":45.68777,"marketCap":6035896875},{"date":"2022-11-11","current":42.347632,"twenty":33.675236,"median":41.160749,"eighty":45.68777,"marketCap":6126050848},{"date":"2022-11-18","current":42.756995,"twenty":33.675236,"median":41.197005,"eighty":45.68777,"marketCap":6185269635},{"date":"2022-11-25","current":43.056379,"twenty":33.675236,"median":41.218321,"eighty":45.68777,"marketCap":6228578896},{"date":"2022-12-02","current":43.196907,"twenty":33.675236,"median":41.257018,"eighty":45.68777,"marketCap":6248907733},{"date":"2022-12-09","current":43.795676,"twenty":33.675236,"median":41.35326,"eighty":45.68777,"marketCap":6335526256},{"date":"2022-12-16","current":43.172467,"twenty":33.675236,"median":41.423201,"eighty":45.68777,"marketCap":6245372283},{"date":"2022-12-23","current":43.685698,"twenty":33.675236,"median":41.463369,"eighty":45.68777,"marketCap":6319616732},{"date":"2022-12-30","current":43.337434,"twenty":33.675236,"median":41.483593,"eighty":45.68777,"marketCap":6269236570},{"date":"2023-01-06","current":43.245786,"twenty":34.167053,"median":41.539601,"eighty":45.68777,"marketCap":6255978633},{"date":"2023-01-13","current":45.714181,"twenty":34.992765,"median":41.587683,"eighty":45.704396,"marketCap":6613059075},{"date":"2023-01-20","current":45.402576,"twenty":35.880519,"median":41.605991,"eighty":45.714503,"marketCap":6567982088},{"date":"2023-01-27","current":45.378137,"twenty":36.169649,"median":41.646285,"eighty":45.714503,"marketCap":6564446638},{"date":"2023-02-03","current":45.255939,"twenty":36.592515,"median":41.674422,"eighty":45.714503,"marketCap":6546769389},{"date":"2023-02-10","current":44.406665,"twenty":36.713651,"median":41.711398,"eighty":45.714503,"marketCap":6423912504},{"date":"2023-02-17","current":44.157808,"twenty":36.89773,"median":41.739833,"eighty":45.714503,"marketCap":6731283715},{"date":"2023-02-24","current":42.410386,"twenty":36.963658,"median":41.754028,"eighty":45.714503,"marketCap":6464912060},{"date":"2023-03-03","current":41.690165,"twenty":37.214665,"median":41.783816,"eighty":45.714503,"marketCap":6355123742},{"date":"2023-03-10","current":39.423241,"twenty":37.286636,"median":41.783816,"eighty":45.714503,"marketCap":6009560514},{"date":"2023-03-17","current":40.355986,"twenty":37.342014,"median":41.783816,"eighty":45.714503,"marketCap":6151745384},{"date":"2023-03-24","current":39.606247,"twenty":37.466803,"median":41.783816,"eighty":45.714503,"marketCap":6037457546},{"date":"2023-03-31","current":40.621801,"twenty":37.536428,"median":41.78137,"eighty":45.714342,"marketCap":6192265465},{"date":"2023-04-06","current":39.692254,"twenty":37.577737,"median":41.783816,"eighty":45.714503,"marketCap":6050568092},{"date":"2023-04-14","current":39.289647,"twenty":37.687654,"median":41.784219,"eighty":45.714663,"marketCap":5989195981},{"date":"2023-04-21","current":39.792905,"twenty":37.872566,"median":41.784621,"eighty":45.714824,"marketCap":6065911119},{"date":"2023-04-28","current":40.118543,"twenty":37.943837,"median":41.797292,"eighty":45.714985,"marketCap":6115550327},{"date":"2023-05-05","current":39.964605,"twenty":38.110019,"median":41.797292,"eighty":45.714985,"marketCap":6092084520},{"date":"2023-05-12","current":39.104119,"twenty":38.249787,"median":41.797292,"eighty":45.714985,"marketCap":6176026400},{"date":"2023-05-19","current":38.898029,"twenty":38.342909,"median":41.797292,"eighty":45.714985,"marketCap":6143476946},{"date":"2023-05-26","current":37.796919,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5969569863},{"date":"2023-06-02","current":37.832249,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5975149770},{"date":"2023-06-09","current":38.668386,"twenty":38.476762,"median":41.797292,"eighty":45.714985,"marketCap":6107207554},{"date":"2023-06-16","current":38.786152,"twenty":38.533217,"median":41.797292,"eighty":45.714985,"marketCap":6125807242},{"date":"2023-06-23","current":38.509402,"twenty":38.553397,"median":41.809962,"eighty":45.718688,"marketCap":6082097976},{"date":"2023-06-30","current":38.55062,"twenty":38.5799,"median":41.81327,"eighty":45.72239,"marketCap":6088607866},{"date":"2023-07-07","current":38.662498,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6106277570},{"date":"2023-07-14","current":38.603615,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6096977726},{"date":"2023-07-21","current":39.357316,"twenty":38.659115,"median":41.81327,"eighty":45.72239,"marketCap":6216015729},{"date":"2023-07-28","current":39.404422,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6223455604},{"date":"2023-08-04","current":38.053978,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6196443469},{"date":"2023-08-11","current":37.511193,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6108060089},{"date":"2023-08-18","current":36.166029,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5889023018},{"date":"2023-08-25","current":36.531819,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5948585730},{"date":"2023-09-01","current":36.472821,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5938978841},{"date":"2023-09-08","current":35.75304,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5821774794},{"date":"2023-09-15","current":35.446248,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5771818971},{"date":"2023-09-22","current":33.711695,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5489376431},{"date":"2023-09-29","current":32.567126,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5303002783},{"date":"2023-10-06","current":32.649724,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5316452427},{"date":"2023-10-13","current":31.806046,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5179073913},{"date":"2023-10-20","current":32.41963,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5278985560},{"date":"2023-10-27","current":33.181375,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5472604212},{"date":"2023-11-03","current":35.377246,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5834769220},{"date":"2023-11-10","current":34.598655,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5706356142},{"date":"2023-11-17","current":35.425908,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5842795038},{"date":"2023-11-24","current":35.170433,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5800659496},{"date":"2023-12-01","current":36.015934,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5940108073},{"date":"2023-12-08","current":36.873602,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6081563104},{"date":"2023-12-15","current":37.7556,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6227031044},{"date":"2023-12-22","current":37.968496,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6262143995},{"date":"2023-12-29","current":38.607184,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":6367482847},{"date":"2024-01-05","current":38.296964,"twenty":38.756995,"median":41.871582,"eighty":45.73451,"marketCap":6316318262},{"date":"2024-01-12","current":38.090151,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":6282208538},{"date":"2024-01-19","current":36.989174,"twenty":38.764196,"median":41.872103,"eighty":45.735522,"marketCap":6100624420},{"date":"2024-01-26","current":36.295741,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":5986256523},{"date":"2024-02-02","current":37.232484,"twenty":38.697827,"median":41.871582,"eighty":45.73451,"marketCap":6140753507},{"date":"2024-02-09","current":35.261674,"twenty":38.661168,"median":41.871582,"eighty":45.73451,"marketCap":5815707904},{"date":"2024-02-16","current":33.847315,"twenty":38.629468,"median":41.871582,"eighty":45.73451,"marketCap":5752655855},{"date":"2024-02-23","current":33.670228,"twenty":38.597685,"median":41.871582,"eighty":45.73451,"marketCap":5722558249},{"date":"2024-03-01","current":32.436519,"twenty":38.556509,"median":41.871061,"eighty":45.733498,"marketCap":5512878257},{"date":"2024-03-08","current":33.758772,"twenty":38.535146,"median":41.871061,"eighty":45.733498,"marketCap":5737607052},{"date":"2024-03-15","current":32.6018,"twenty":38.489062,"median":41.871061,"eighty":45.733498,"marketCap":5540969356},{"date":"2024-03-22","current":33.262927,"twenty":38.456408,"median":41.871061,"eighty":45.733498,"marketCap":5653333754},{"date":"2024-03-28","current":33.457723,"twenty":38.385748,"median":41.784621,"eighty":45.733498,"marketCap":5686441121},{"date":"2024-04-05","current":33.192092,"twenty":38.338315,"median":41.766476,"eighty":45.73451,"marketCap":5641294711},{"date":"2024-04-12","current":33.499043,"twenty":38.271415,"median":41.746116,"eighty":45.73451,"marketCap":5693463896},{"date":"2024-04-19","current":32.99201,"twenty":38.226469,"median":41.73308,"eighty":45.73451,"marketCap":5607289064},{"date":"2024-04-26","current":33.647761,"twenty":38.150217,"median":41.720309,"eighty":45.733498,"marketCap":5827926731},{"date":"2024-05-03","current":33.618779,"twenty":38.090151,"median":41.711398,"eighty":45.733498,"marketCap":5822906984},{"date":"2024-05-10","current":34.482434,"twenty":38.029323,"median":41.69585,"eighty":45.733498,"marketCap":5972495456},{"date":"2024-05-17","current":34.986715,"twenty":37.950247,"median":41.66791,"eighty":45.733498,"marketCap":6059839061},{"date":"2024-05-24","current":34.198413,"twenty":37.871294,"median":41.619337,"eighty":45.733498,"marketCap":5923301932},{"date":"2024-05-31","current":34.928752,"twenty":37.820473,"median":41.602226,"eighty":45.733498,"marketCap":6049799566},{"date":"2024-06-07","current":35.908334,"twenty":37.7418,"median":41.585665,"eighty":45.733498,"marketCap":6219467028},{"date":"2024-06-14","current":35.311311,"twenty":37.642264,"median":41.478607,"eighty":45.73451,"marketCap":6116060232},{"date":"2024-06-21","current":35.485201,"twenty":37.563829,"median":41.447441,"eighty":45.735522,"marketCap":6146178716},{"date":"2024-06-28","current":35.734443,"twenty":37.537078,"median":41.447441,"eighty":45.738558,"marketCap":6189348544},{"date":"2024-07-05","current":35.879352,"twenty":37.482188,"median":41.447441,"eighty":45.738558,"marketCap":6214447281},{"date":"2024-07-12","current":36.957471,"twenty":37.418215,"median":41.439295,"eighty":45.738558,"marketCap":6401181884},{"date":"2024-07-15","current":37.189325,"twenty":37.412399,"median":41.439295,"eighty":45.738558,"marketCap":6441339863},{"date":"2024-08-02","current":37.993919,"twenty":37.339153,"median":41.40142,"eighty":45.707657,"marketCap":7107142493},{"date":"2024-08-09","current":38.417922,"twenty":37.339153,"median":41.351038,"eighty":45.669183,"marketCap":7186456557},{"date":"2024-08-16","current":38.455492,"twenty":37.339153,"median":41.248609,"eighty":45.587895,"marketCap":7193484385},{"date":"2024-08-23","current":38.879496,"twenty":37.339153,"median":41.197005,"eighty":45.51208,"marketCap":7272798449},{"date":"2024-08-30","current":39.104915,"twenty":37.339153,"median":41.152223,"eighty":45.432939,"marketCap":7314965420},{"date":"2024-09-06","current":40.19981,"twenty":37.339153,"median":41.109476,"eighty":45.406991,"marketCap":7519776420},{"date":"2024-09-13","current":40.725789,"twenty":37.339153,"median":41.060268,"eighty":45.379705,"marketCap":7618166018},{"date":"2024-09-20","current":39.786541,"twenty":37.339153,"median":41.020981,"eighty":45.296882,"marketCap":7442470307},{"date":"2024-09-27","current":39.931453,"twenty":37.339153,"median":40.992653,"eighty":45.271719,"marketCap":7469577645},{"date":"2024-10-04","current":40.355457,"twenty":37.339153,"median":40.937316,"eighty":45.211095,"marketCap":7548891709},{"date":"2024-10-11","current":39.3196,"twenty":37.339153,"median":40.894276,"eighty":45.159517,"marketCap":7355124439},{"date":"2024-10-18","current":40.731156,"twenty":37.339153,"median":40.838938,"eighty":45.089028,"marketCap":7619169993},{"date":"2024-10-25","current":42.532506,"twenty":37.339153,"median":40.820493,"eighty":45.046981,"marketCap":8077475775},{"date":"2024-10-31","current":40.816625,"twenty":37.339153,"median":40.816625,"eighty":44.988744,"marketCap":7751607762},{"date":"2024-11-08","current":40.076878,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7611120201},{"date":"2024-11-15","current":41.115788,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7808422584},{"date":"2024-11-22","current":41.948003,"twenty":37.338438,"median":40.773001,"eighty":44.914929,"marketCap":7966471090},{"date":"2024-11-29","current":41.773945,"twenty":37.338438,"median":40.773001,"eighty":44.914324,"marketCap":7933415193},{"date":"2024-12-06","current":40.849261,"twenty":37.338438,"median":40.770318,"eighty":44.892115,"marketCap":7757805742},{"date":"2024-12-13","current":40.055121,"twenty":37.338438,"median":40.736734,"eighty":44.892115,"marketCap":7606988214},{"date":"2024-12-20","current":37.770608,"twenty":37.338438,"median":40.680888,"eighty":44.892115,"marketCap":7173129570},{"date":"2024-12-27","current":38.515795,"twenty":37.338438,"median":40.640959,"eighty":44.892115,"marketCap":7314650128},{"date":"2025-01-03","current":37.933788,"twenty":37.338438,"median":40.614232,"eighty":44.892115,"marketCap":7204119473},{"date":"2025-01-10","current":37.906591,"twenty":37.337724,"median":40.580698,"eighty":44.89414,"marketCap":7198954490},{"date":"2025-01-17","current":39.244663,"twenty":37.333873,"median":40.538993,"eighty":44.89414,"marketCap":7453071695},{"date":"2025-01-24","current":38.87479,"twenty":37.333873,"median":40.501145,"eighty":44.89414,"marketCap":7382827915},{"date":"2025-01-31","current":39.761398,"twenty":37.333873,"median":40.465332,"eighty":44.84311,"marketCap":7551206388},{"date":"2025-02-07","current":39.74508,"twenty":37.333873,"median":40.424995,"eighty":44.718497,"marketCap":7548107398},{"date":"2025-02-14","current":40.634976,"twenty":37.333873,"median":40.403761,"eighty":44.67404,"marketCap":7688015540},{"date":"2025-02-21","current":40.363435,"twenty":37.333873,"median":40.374953,"eighty":44.653159,"marketCap":7636640801},{"date":"2025-02-28","current":41.687197,"twenty":37.333873,"median":40.374953,"eighty":44.559412,"marketCap":7887092651},{"date":"2025-03-07","current":42.394335,"twenty":37.33306,"median":40.37194,"eighty":44.562299,"marketCap":8020881032},{"date":"2025-03-14","current":42.767704,"twenty":37.33306,"median":40.383179,"eighty":44.562299,"marketCap":8091521298},{"date":"2025-03-21","current":43.141073,"twenty":37.417052,"median":40.40791,"eighty":44.562299,"marketCap":8162161563},{"date":"2025-03-28","current":42.993988,"twenty":37.479862,"median":40.452151,"eighty":44.562299,"marketCap":8134333580},{"date":"2025-04-04","current":43.440899,"twenty":37.536428,"median":40.487288,"eighty":44.562299,"marketCap":8218887836},{"date":"2025-04-11","current":41.268572,"twenty":37.537078,"median":40.501145,"eighty":44.559412,"marketCap":7807889929},{"date":"2025-04-17","current":44.145605,"twenty":37.540692,"median":40.519212,"eighty":44.559412,"marketCap":8352216066},{"date":"2025-04-25","current":43.782817,"twenty":37.571542,"median":40.572736,"eighty":44.653759,"marketCap":8377141546},{"date":"2025-05-02","current":45.953462,"twenty":37.571542,"median":40.583839,"eighty":44.677947,"marketCap":8792459672},{"date":"2025-05-09","current":43.031008,"twenty":37.571542,"median":40.598117,"eighty":44.677947,"marketCap":8233294969},{"date":"2025-05-16","current":42.422675,"twenty":37.571542,"median":40.624906,"eighty":44.677947,"marketCap":8116900028},{"date":"2025-05-23","current":42.755537,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8180587826},{"date":"2025-05-30","current":42.698147,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8169607171},{"date":"2025-06-06","current":42.411197,"twenty":37.571542,"median":40.666871,"eighty":44.666838,"marketCap":8114703897},{"date":"2025-06-13","current":42.927706,"twenty":37.571542,"median":40.666871,"eighty":44.666838,"marketCap":8213529790},{"date":"2025-06-20","current":43.220395,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":8269531129},{"date":"2025-06-27","current":41.894687,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":8015878004},{"date":"2025-07-03","current":41.30357,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7902777259},{"date":"2025-07-11","current":40.735409,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7794068777},{"date":"2025-07-18","current":41.234702,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7889600473},{"date":"2025-07-25","current":42.319373,"twenty":37.604201,"median":40.725789,"eighty":44.606841,"marketCap":8097134849},{"date":"2025-08-01","current":42.372392,"twenty":37.604201,"median":40.742491,"eighty":44.606841,"marketCap":7873129491},{"date":"2025-08-08","current":43.918584,"twenty":37.604201,"median":40.752858,"eighty":44.633348,"marketCap":8160424292},{"date":"2025-08-15","current":42.901923,"twenty":37.604201,"median":40.790693,"eighty":44.633348,"marketCap":7971520467},{"date":"2025-08-22","current":44.019656,"twenty":37.604201,"median":40.820493,"eighty":44.633348,"marketCap":8179204204},{"date":"2025-08-29","current":43.199192,"twenty":37.604201,"median":40.894276,"eighty":44.633348,"marketCap":8026755504},{"date":"2025-09-05","current":42.806797,"twenty":37.595885,"median":40.935905,"eighty":44.639951,"marketCap":7953845256},{"date":"2025-09-12","current":43.841294,"twenty":37.604201,"median":40.969944,"eighty":44.633348,"marketCap":8146063183},{"date":"2025-09-19","current":42.527363,"twenty":37.604201,"median":41.008406,"eighty":44.633348,"marketCap":7901924321},{"date":"2025-09-26","current":41.962551,"twenty":37.639342,"median":41.035693,"eighty":44.633348,"marketCap":7796977752},{"date":"2025-10-03","current":42.027951,"twenty":37.639342,"median":41.102705,"eighty":44.633348,"marketCap":7809129460},{"date":"2025-10-10","current":41.974442,"twenty":37.639342,"median":41.115788,"eighty":44.633348,"marketCap":7799187153},{"date":"2025-10-17","current":44.322871,"twenty":37.639342,"median":41.17126,"eighty":44.633348,"marketCap":8235543942},{"date":"2025-10-24","current":44.544295,"twenty":37.639342,"median":41.220151,"eighty":44.656944,"marketCap":8621592904},{"date":"2025-10-31","current":43.1986,"twenty":37.639342,"median":41.2516,"eighty":44.656944,"marketCap":8361132219},{"date":"2025-11-07","current":42.991114,"twenty":37.639342,"median":41.30357,"eighty":44.656944,"marketCap":8320973082},{"date":"2025-11-14","current":43.690638,"twenty":37.639342,"median":41.35326,"eighty":44.656944,"marketCap":8456366743},{"date":"2025-11-21","current":43.68471,"twenty":37.639342,"median":41.452784,"eighty":44.656944,"marketCap":8455219339},{"date":"2025-11-28","current":44.591721,"twenty":37.639342,"median":41.521652,"eighty":44.656944,"marketCap":8630772135},{"date":"2025-12-05","current":44.093754,"twenty":37.639342,"median":41.583569,"eighty":44.656944,"marketCap":8534390208},{"date":"2025-12-12","current":42.244164,"twenty":37.639342,"median":41.619337,"eighty":44.656944,"marketCap":8176400191},{"date":"2025-12-19","current":42.902191,"twenty":37.639342,"median":41.692355,"eighty":44.656944,"marketCap":8303762024},{"date":"2025-12-26","current":42.919976,"twenty":37.639342,"median":41.746748,"eighty":44.656944,"marketCap":8307204236},{"date":"2026-01-02","current":42.700633,"twenty":37.639342,"median":41.754028,"eighty":44.656944,"marketCap":8264750291},{"date":"2026-01-09","current":41.977396,"twenty":37.639342,"median":41.778924,"eighty":44.654358,"marketCap":8124767015},{"date":"2026-01-16","current":42.688777,"twenty":37.639342,"median":41.778924,"eighty":44.603089,"marketCap":8262455483},{"date":"2026-01-23","current":42.700633,"twenty":37.639342,"median":41.778924,"eighty":44.565186,"marketCap":8264750291},{"date":"2026-01-30","current":42.659136,"twenty":37.639342,"median":41.778924,"eighty":44.544295,"marketCap":8256718464},{"date":"2026-02-06","current":45.131184,"twenty":37.639342,"median":41.778924,"eighty":44.513975,"marketCap":8735185890},{"date":"2026-02-10","current":44.639146,"twenty":37.639342,"median":41.778924,"eighty":44.506847,"marketCap":8639951367}],"updateTime":1770845095805},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610616389","title":"西南證券：驅動基因陰性NSCLC市場空間廣闊 雙(多)抗、IO+ADC方案齊頭並進","url":"https://stock-news.laohu8.com/highlight/detail?id=2610616389","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610616389?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 14:50","pubTimestamp":1770706257,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，目前一线治疗驱动基因阴性NSCLC晚期患者主要依赖PD-1±化疗的治疗方案，测算2030年用于驱动基因阴性NSCLC晚期一线治疗的免疫用药中美市场规模分别约为75亿元、180亿元。NSCLC下一代免疫治疗方案齐头并进，为双(多)抗以及IO+ADC。西南证券主要观点如下：驱动基因阴性空间几何?驱动基因阴性指肿瘤样本中未检测到明确可靶向的驱动基因突变，分别占中美患者新发NSCLC患者的31%/31%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0276","ADC","BK4080","BK4231","BK0183","BK0028","BK0012","600369","BK0188"],"gpt_icon":0},{"id":"2610661036","title":"中國生物製藥(01177)：TQB2102「HER2雙抗ADC」HER2低表達乳腺癌III期臨牀試驗完成受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2610661036","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610661036?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 06:16","pubTimestamp":1770675411,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团自主研发的国家1类创新药TQB2102“HER2双抗ADC”正在开展一项“评价注射用TQB2102对比研究者选择的化疗在HER2低表达复发╱转移性乳腺癌中有效性和安全性的随机、开放、平行对照的III期临床试验”，近期已完成全部受试者入组。以上核心技术的结合，突破了传统HER2单抗及单靶点ADC的局限，使TQB2102在HER2低表达肿瘤治疗中展现出显著潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK4134","01177","BK4231","HK0000165453.HKD","BK1515","III","IE00BZ08YT58.USD","BK1191","BK1589","BK1521","IE00BZ08YS42.EUR","ADC","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2610502918","title":"港股異動 | 石藥集團(01093)升逾3% 機構看好公司未來在EGFR ADC及研發平台將有更多對外授權合作機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2610502918","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610502918?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 10:35","pubTimestamp":1770604509,"startTime":"0","endTime":"0","summary":"消息面上，汇丰研究发布研究报告指出，石药集团股价年初至今累计上涨约9%，在1月30日公布与阿斯利康的合作前已升14%，目前认为其估值仍然吸引，并憧憬未来在EGFR ADC及研发平台将有更多对外授权合作机会，计及预付款及上季销售轻微改善的预期，将2025至2027年收入预测上调3%至11%。该行并将石药集团2025至2027年净利润预测上调7%至18%，认为对外授权收入的增长已能抵销药品集中带量采购政策所带来的负面影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","LU1226287529.USD","BK1515","BK4080","LU2039709279.SGD","LU1993786604.SGD","VXUS","LU1152091754.HKD","LU0501845795.SGD","LU0067412154.USD","LU0880133367.SGD","LU0314109678.HKD","LU1226288170.HKD","VT","BK4588","LU0072913022.USD","LU1226287792.SGD","IE0008369823.USD","IE00BZ08YR35.GBP","IE00B543WZ88.USD","LU0140636845.USD","LU1152091168.USD","LU1807302812.USD","LU1226287875.USD","LU1226288253.USD","BK1191","BK4231","IE0008368742.USD","IE00B031HY20.USD","LU1008478684.HKD","01093","SG9999004220.SGD","IE00BZ08YS42.EUR","LU1951186391.HKD","IE00B5MMRT66.SGD","LU1813983027.USD","BK1521","IE00BZ08YT58.USD","LU0326950275.SGD","BK4585","LU1960683339.HKD","ADC","LU0315179316.USD","LU1328277881.USD"],"gpt_icon":0},{"id":"2610503880","title":"中國生物製藥(01177)：維特柯妥拜單抗「CLDN18.2 ADC」III期臨牀試驗完成受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2610503880","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610503880?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 06:15","pubTimestamp":1770588951,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团全资附属公司礼新医药科技(上海)有限公司自主研发的国家1类创新药维特柯妥拜单抗“CLDN18.2 ADC”正在开展用于治疗三线及以上CLDN18.2阳性的局部晚期或转移性胃及胃食管交界部腺癌的III期注册临床试验，已顺利完成患者入组。其中，LM302是全球首款完成注册III期临床试验入组的CLDN18.2 ADC药物。该研究表明，LM302联合治疗方案在CLDN18.2阳性患者中展现出显著的抗肿瘤活性和可管理的安全性特征。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1191","BK1515","BK4231","01177","ADC","BK4134","IE00BZ08YS42.EUR","III","HK0000165453.HKD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1521","BK4080"],"gpt_icon":0},{"id":"2609239712","title":"Macrogenics, Inc.盤中異動 股價大跌5.43%報1.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609239712","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609239712?lang=zh_tw&edition=fundamental","pubTime":"2026-02-05 00:57","pubTimestamp":1770224260,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日00时57分，Macrogenics, Inc.股票出现波动，股价快速下跌5.43%。Macrogenics, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Liminatus Pharma, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Biodexa Pharmaceuticals Plc、Gri Bio, Inc.、Evogene Ltd.较为活跃，换手率分别为412.61%、208.91%、134.97%，振幅较大的相关个股有Liminatus Pharma, Inc.、Celularity Inc C/Wts 16/07/2026 、Liminatus Pharma Inc C/Wts 30/04/2030 ，振幅分别为65.42%、61.25%、35.30%。Macrogenics, Inc.公司简介：Macrogenics Inc是一家生物技术公司，专注于发现和开发用于治疗癌症的基于抗体的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020500574197a4e59c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020500574197a4e59c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADC","MGNX","BK4231","BK4139","BK4080"],"gpt_icon":0},{"id":"2608354549","title":"貝達藥業：公司自研尚未有ADC產品項目立項","url":"https://stock-news.laohu8.com/highlight/detail?id=2608354549","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608354549?lang=zh_tw&edition=fundamental","pubTime":"2026-02-04 17:22","pubTimestamp":1770196934,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)02月04日在投资者关系平台上答复投资者关心的问题。投资者提问：据公开信息，公司多次提到布局ADC产品项目。请问董秘，这是自研产品还是从生态圈战略合作伙伴引进？贝达药业回复：您好！公司自研尚未有ADC产品项目立项，将通过生态圈联动合作伙伴积极关注ADC产品项目，后续如有相关重大节点进展，公司会及时公开披露。谢谢！为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260204/31998153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300558","BK0060","BK4080","BK4231","BK0239","ADC"],"gpt_icon":0},{"id":"1132811598","title":"Pyxis Oncology宣佈臨時CEO任命及領導層交接，聚焦戰略重點與項目延續性","url":"https://stock-news.laohu8.com/highlight/detail?id=1132811598","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132811598?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 19:49","pubTimestamp":1770119377,"startTime":"0","endTime":"0","summary":"波士顿，2026年2月3日——临床阶段生物制药公司Pyxis Oncology, Inc.今日宣布领导层交接计划，旨在持续推进公司战略与临床目标的执行。自公司首次公开募股以来一直担任董事会成员的Thomas Civik被任命为临时首席执行官，即刻生效。通过此次人事调整，Pyxis Oncology将由深度熟悉公司战略及研发项目的资深领导者掌舵。董事会主席John Flavin表示：\"任命Tom为临时CEO是为了确保领导力的稳健过渡与业务连续性。Pyxis Oncology已奠定坚实的科研与临床基础，我们对核心项目的前景保持乐观。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4588","ADC","BK4080","BK4585","PYXS","LU2487616109.SGD","LU0053666078.USD","LU0210528500.USD","BK4231","BK4232","BK4107","R","BK4139","L"],"gpt_icon":0},{"id":"1131684922","title":"財報前瞻｜艾格里房產本季度營收預計增18.63%，機構觀點偏積極","url":"https://stock-news.laohu8.com/highlight/detail?id=1131684922","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131684922?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 10:33","pubTimestamp":1770086001,"startTime":"0","endTime":"0","summary":"艾格里房产将在2026年02月10日发布最新季度财报，市场关注其租金收入增长与利润率表现，以及管理层对净利润和EPS的指引与执行力。市场一致预期显示，本季度艾格里房产总收入预计为1.86亿美元，同比增长18.63%；毛利率预计维持高位但未给出具体预测值；净利润或净利率本季度未形成明确一致预期；调整后每股收益预计为0.47美元，同比增长9.77%；EBIT预计为9,678.30万美元，同比增速26.16%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜艾格里房产本季度营收预计增18.63%，机构观点偏积极","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC"],"gpt_icon":0},{"id":"2607773294","title":"千億藥明系，連環資本局","url":"https://stock-news.laohu8.com/highlight/detail?id=2607773294","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607773294?lang=zh_tw&edition=fundamental","pubTime":"2026-01-29 10:25","pubTimestamp":1769653543,"startTime":"0","endTime":"0","summary":"收购与出售药明系的资本动作，一轮接一轮。药明系资本运作1.02015年，上市美股8年的药明康德提出私有化方案。之后，药明康德多次澄清，李革团队也推出回购计划。药明系资本运作2.0根据业绩预告，2025年药明康德实现营收、经调整归母净利润、扣非净利润分别为454.56亿元、149.57亿元、132.4亿元，同比增长15.84%、41.33%、32.56%。另一方面，药明康德的研发投入收缩，2025年前三季度同比下降13.7%，研发费用率2.5%，较2024年同期的3.4%有明显下滑。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1769221590141206927","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0051755006.USD","IE00B0JY6N72.USD","BK1610","603259","LU0856984785.SGD","LU0140636845.USD","LU0359201612.USD","LU0516422952.EUR","BK0216","LU0516422366.SGD","BK1589","LU1934453819.USD","BK4231","LU1688375341.USD","LU2488822045.USD","CDMO","LU0039217434.USD","BK4139","LU0819121731.USD","LU0708995583.HKD","LU0823426480.USD","LU1997245177.USD","LU0979878070.USD","SG9999014674.SGD","BK1141","LU0456842615.SGD","SG9999002562.SGD","LU0052750758.USD","LU1997244956.HKD","ADC","LU1720050803.USD","LU0327786744.USD","BK4080","LU0456827905.SGD","02268","BK1576","LU0417516738.SGD","LU0359202008.SGD","LU0456846285.SGD","LU0326950275.SGD","LU3063872942.SGD","LU2328871848.SGD","BK1521","SG9999002463.SGD","LU1242518931.SGD","02269","LU0307460666.USD","LU0348735423.USD","LU1997245094.SGD","LU0516423091.SGD"],"gpt_icon":0},{"id":"2606376243","title":"東方證券：IO和ADC為腫瘤頭部MNC焦點 聯用將迎突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2606376243","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606376243?lang=zh_tw&edition=fundamental","pubTime":"2026-01-28 14:13","pubTimestamp":1769580821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方证券发布研报称，JPM 2026大会上肿瘤领域头部MNC将IO和ADC作为战略重心，且十分重视联合疗法的开发，其中二代IO多来自国产企业，sac-TMT在ADC中地位突出，今年是IO联合ADC确定性提升的关键节点，未来ADC尤其是泛瘤种ADC的需求有望进一步提升。另一方面，围绕IO和ADC的联用探索正全面加速，默沙东已开展9项sac-TMT联用K药的III期临床研究，BMS将推进BNT327与ADC的联用，辉瑞计划今年开展SSGJ-707和ADC联用的III期临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK1564","BK1147","BK0012","BK0276","BK0188","BK4231","ADC","03958","600958","BK4080","BK0028"],"gpt_icon":0},{"id":"2606258771","title":"每周股票覆盤：百利天恒（688506）EGFR×HER3雙抗ADC上市申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2606258771","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606258771?lang=zh_tw&edition=fundamental","pubTime":"2026-01-25 09:01","pubTimestamp":1769302867,"startTime":"0","endTime":"0","summary":"本周，百利天恒1月19日盘中最高价报316.86元。来自公司公告汇总：百利天恒EGFR×HER3双抗ADC药物iza-bren上市申请获国家药监局受理。来自公司公告汇总：百利天恒将于2026年2月9日召开临时股东会审议H股延期等议案。1月21日百利天恒发生一笔269.67万元的大宗交易。四川百利天恒药业股份有限公司自愿披露，其自主研发的EGFR×HER3双抗ADC药物iza-bren用于治疗复发性或转移性食管鳞癌的药品上市申请已获国家药监局药品审评中心受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260125/31970168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["ADC","BK0239","BK4080","BK4231","91194","688506","02615"],"gpt_icon":0},{"id":"2605034473","title":"優赫得在華拓展第六個適應症，去年上半年銷售額突破22億美金","url":"https://stock-news.laohu8.com/highlight/detail?id=2605034473","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605034473?lang=zh_tw&edition=fundamental","pubTime":"2026-01-23 17:13","pubTimestamp":1769159628,"startTime":"0","endTime":"0","summary":"2024 年全球已获批上市的 17 款 ADC 药物合计销售额达百亿美金，其中第一三共的德曲妥珠单抗表现尤为突出，2024 年销售额达到 34.8 亿美元、同比增长 52%。根据阿斯利康2025年上半年财报，其自身销售额为12.6亿美元，增长38%；包括合作伙伴第一三共报告的销售额在内，总销售额为22.9亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1769159310955231385","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["OS","BK4195","BK4231","BK4080","ORR","BK4211","PFS","ADC","BK4097"],"gpt_icon":0},{"id":"2605989254","title":"德曲妥珠單抗胃癌新適應證獲批，填補臨牀治療空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2605989254","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605989254?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 19:18","pubTimestamp":1769080687,"startTime":"0","endTime":"0","summary":"由阿斯利康和第一三共共同开发与商业化的优赫得（英文商品名：Enhertu，通用名：注射用德曲妥珠单抗）今天获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627553572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","BK4195","BK4231","OS","BK4097","BK4211","ORR","ADC","PFS"],"gpt_icon":0},{"id":"2605495703","title":"優赫得®在華獲批治療既往接受過一種含曲妥珠單抗治療方案的局部晚期或轉移性HER2陽性成人胃或胃食管結合部腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495703","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605495703?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 18:38","pubTimestamp":1769078280,"startTime":"0","endTime":"0","summary":"研究显示，对于局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者，与雷莫西尤单抗+紫杉醇相比，德曲妥珠单抗带来具有显著统计学差异和临床意义的总生存期改善。自一年多前首次在中国获批用于HER2阳性局部晚期或转移性胃癌以来，德曲妥珠单抗仅可用于三线及后线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4868984_ZH68984_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0868494617.USD","LU1221951046.USD","BK4231","LU2506951875.HKD","BK4585","PFS","SG9999015945.SGD","LU0320765992.SGD","LU1880398554.USD","LU2462157665.USD","BK4612","LU2237443895.HKD","LU2417539215.USD","LU1066053197.SGD","SG9999001440.SGD","LU1046421795.USD","LU2237443382.USD","LU2247934214.USD","SG9999015978.USD","ADC","AZN","LU1571399168.USD","ORR","LU1244550494.USD","BK4527","BK4579","LU1221951129.SGD","LU1244550577.SGD","BK4195","IE00BKVL7J92.USD","LU2237443549.SGD","LU2506951958.HKD","LU0109394709.USD","BK4588","LU2506952097.USD","CSCO","OS","LU1196500208.SGD","LU0234572021.USD","BK4080","BK4560","IE00BFMHRM44.USD","LU0792757196.USD","LU1066051498.USD","LU1880398471.USD","LU1929549753.HKD","IE000M9KFDE8.USD","LU2237443622.USD","LU1894683348.USD","BK4097"],"gpt_icon":0},{"id":"2605696344","title":"優赫得在華獲批新適應症","url":"https://stock-news.laohu8.com/highlight/detail?id=2605696344","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605696344?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 16:46","pubTimestamp":1769071572,"startTime":"0","endTime":"0","summary":"南方财经1月22日电，记者获悉，由阿斯利康和第一三共共同开发与商业化的优赫得?（英文商品名：Enhertu?，通用名：注射用德曲妥珠单抗）获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627420221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","ADC","BK4231"],"gpt_icon":0},{"id":"2605846678","title":"全球首創！百利天恒ADC新藥IZA-BREN食管鱗癌適應症獲CDE受理，中國患者有望領先海外三年獲益","url":"https://stock-news.laohu8.com/highlight/detail?id=2605846678","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605846678?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 16:45","pubTimestamp":1769071524,"startTime":"0","endTime":"0","summary":"其中，中国是食管癌高发国家，新发食管癌患者约22.4万人，占全球43.8%，是全球食管癌患病人数和死亡人数最多的国家。这款全球首创的新药，一旦在中国获批，意味着中国患者将有望领先海外约三年，率先获益于此创新治疗方案。除了食管鳞癌的二线适应症，根据此前公告，iza-bren其复发/转移性鼻咽癌NDA已于2025年11月获受理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1769071296067530107","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU1223083913.SGD","91194","02615","CDE","BK4231","LU1223082519.USD","ADC","BK0239","BK4017","LU1223082196.USD","BK4080","688506"],"gpt_icon":0},{"id":"2605667194","title":"華福證券：首次覆蓋維立志博(09887)給予「買入」評級 下一代IO和ADC療法全佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2605667194","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605667194?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 15:38","pubTimestamp":1769067529,"startTime":"0","endTime":"0","summary":"首次覆盖维立志博给予“买入”评级，预计维立志博2025-2027年营业收入分别为1.80、0.94、0.10亿元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260122/20260122154150_41671.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260122/20260122154150_41671.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09887","161027","ADC"],"gpt_icon":0},{"id":"2604185921","title":"繼鼻咽癌後瞄準食管鱗癌二線治療 百利天恒雙抗ADC第二項上市申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2604185921","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604185921?lang=zh_tw&edition=fundamental","pubTime":"2026-01-20 20:24","pubTimestamp":1768911859,"startTime":"0","endTime":"0","summary":"1月20日，CDE官网披露，百利天恒旗下核心管线iza-bren的第二项上市申请获得受理。该适应证用于治疗既往经PD-1/PD-L1单抗联合含铂化疗治疗失败的复发性或转移性食管鳞癌。食管鳞癌的后线治疗是临床上面临的主要挑战。一旦一线免疫联合化疗方案失败，患者的治疗选择便急剧收窄。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601203624904478.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624904478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","688506","91194","ADC","BK4080","02615","BK0239"],"gpt_icon":0},{"id":"2604194956","title":"雙抗ADC又一歷史性突破！百利天恒(688506.SH)iza-bren食管鱗癌上市申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2604194956","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604194956?lang=zh_tw&edition=fundamental","pubTime":"2026-01-20 18:56","pubTimestamp":1768906588,"startTime":"0","endTime":"0","summary":"当中国的实验室里诞生的分子结构，开始被写入全球顶级药企的研发管线；当中国患者面临的特殊疾病谱，开始由本土研发的首创疗法来攻克——中国医药创新的新纪元已经到来。iza-bren的上市之路，正引领着这场深刻的变革。","market":"sh","thumbnail":"https://img2.gelonghui.com/e55e7-e105614b-cfcf-47e0-a047-56d3689a65f1.jpg?guru_height=1080&guru_width=1920&guru_size=326598","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/e55e7-e105614b-cfcf-47e0-a047-56d3689a65f1.jpg?guru_height=1080&guru_width=1920&guru_size=326598"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3629906","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4231","688506","91194","ADC","BK4080","02615","BK0239"],"gpt_icon":0},{"id":"2604157635","title":"港股異動 | 映恩生物-B(09606)早盤升逾4% ADAM9靶向ADC癌症新藥在中國獲批臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2604157635","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604157635?lang=zh_tw&edition=fundamental","pubTime":"2026-01-20 09:48","pubTimestamp":1768873737,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B早盘涨超4%，截至发稿，涨2.42%，报363.6港元，成交额5105.75万港元。消息面上，1月19日，映恩生物宣布，公司自主研发的ADAM9靶向抗体偶联药物DB-1317已获得国家药监局药品审评中心的新药临床试验批准，同意其单药在晚期/转移性恶性实体瘤患者中开展临床试验。据悉，DB-1317是映恩生物基于公司自主研发的ADC技术平台DITAC开发的新一代ADC产品，具有全球权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606","BK4080","BK4231","HK0000252152.HKD","HK0000500386.USD","LU2543165471.USD","HK0000252160.HKD","BK1161","ADC"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":196,"code":"91000000","status":"200"}]}}